Efficacy and safety of vitamin K + lenvatinib combination treatment against hepatocellular carcinoma:a randomised,open label,phase 2 trial

Efficacy and safety of vitamin K + lenvatinib combination treatment against hepatocellular carcinoma:a randomised,open label,phase 2 trial - Vitamin K + lenvatinib combination treatment against HCC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033027

Enrollment

Registered

2018-06-17

Start date

2018-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

lenvatinib(12mg or 8mg, daily) alone treatment, continued if neither severe adverse events nor disease progression is seen lenvatinib(12mg or 8mg, daily)+vitamin K(45mg, daily) combination treatment,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ECOG performance status: 0 or 1 Child-Pugh score: 8 or less suffering with osteoporosis Written consent is obtained.

Exclusion criteria

Exclusion criteria: dosed with warfarin

Design outcomes

Primary

Measure	Time frame
progression free survival(evaluated by modified RECIST)	—

Secondary

Measure	Time frame
overall survival safety (comparison in adverse event incidence)	—

Countries

Japan

Contacts

Public ContactYoshimichi Haruna

Osaka General Medical Center Departments of Laboratory Medicine and Gastroenterology & Hepatology

apple-123-grape@ab.auone-net.jp06-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026